Standout Papers

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multi... 2019 2026 2021 2023 351
  1. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial (2019)
    Vicky Makker, Drew Rasco et al. The Lancet Oncology

Immediate Impact

12 by Nobel laureates 22 from Science/Nature 58 standout
Sub-graph 1 of 23

Citing Papers

Tumour vasculature at single-cell resolution
2024 StandoutNature
Theranostic Fluorescent Probes
2024 Standout
3 intermediate papers

Works of Christopher Di Simone being referenced

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
Christopher Di Simone 104 270 65 135 113 10 577
Brigitte A. Barrette 85 268 153 62 137 12 713
Walter M. Klein 73 318 41 40 168 13 556
Neelam B. Kumar 135 170 275 55 57 11 625
Chih‐Chien Cheng 86 113 18 59 121 23 547
Ryuichi Nakashima 43 135 240 73 210 18 594
R Martucci 32 223 91 42 148 12 669
Kum Cooper 88 394 91 63 68 18 661
MarkH. Greene 30 304 151 41 124 8 731
Patrizia Ceruti 53 131 34 62 154 13 611
Kate Poropatich 154 154 67 106 125 16 587

All Works

Loading papers...

Rankless by CCL
2026